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Abstract Vanadium is a trace element widely distributed
in the environment. In vertebrates it is mainly stored in
bone tissue. The unique cellular environment in the bone
and the variety of interactions that mediate cancer metasta-
sis determine that certain types of cancer, such as breast
and prostate cancer, preferentially metastize in the skeleton.
Since this eVect usually signiWes serious morbidity and
grave prognosis there is an increasing interest in the devel-
opment of new treatments for this pathology. The present
work shows that vanadium complexes can inhibit some
parameters related to cancer metastasis such as cell adhe-
sion, migration and clonogenicity. We have also investi-
gated the role of protein kinase A in these processes.
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Introduction
Vanadium is a trace element widely distributed in the envi-
ronment [24]. After being orally absorbed, vanadium is rap-
idly distributed in tissues (lungs, kidneys, spleen and
muscle), and it is mainly stored in bone [29]. It has been
demonstrated that vanadium can exert speciWc eVects on
skeletal tissue such as to induce bone and teeth mineraliza-
tion [24], to stimulate osteoblast proliferation and diVeren-
tiation as well as collagen synthesis [2, 6]. There are also
evidences that vanadium is accumulated in higher amounts
in neoplastic cells than in non-transformed ones [15].
Recent studies indicate the role of vanadium as a chemical
preventive agent in some tumoral animal models, human
cancer cell lines and also in certain xenografted human car-
cinomas [20, 27]. On the other hand, using in vitro models
it has been shown that some vanadium complexes dis-
played antitumoral actions [3, 8, 9, 11, 15, 22].
Breast and prostate cancer preferentially metastasize in
the skeleton, and this eVect usually signiWes serious mor-
bidity and grave prognosis. The unique cellular environ-
ment in the bone and the variety of interactions that mediate
cancer metastasis growth are just being identiWed [31].
Although the precise molecular mechanism that governs
bone metastasis has not been clearly identiWed yet, it has
been suggested that bone provides the microenvironment
that allows cancer cells to arrest, growth, colonize and sur-
vive [31]. In the neoplasic process there are three key
events that determine tumour growth and dissemination.
These processes are cell adhesion to the extracellular
matrix (ECM), cell clonogenicity and cell migration from
the tumour mass to invade the ECM and colonize distant
tissues in the host [1, 31]. Under this perspective, those
drugs which are able to aVect these key events may be use-
full in antitumoral treatments.
Previous results from our research group have shown
that vanadium(IV) derivatives with some non-steroidal
anti-inXammatory drugs such as naproxen, as well as some
vanadyl(IV) complexes with mono- and disaccharides (like
glucose and trehalose), displayed antitumoral properties in
an osteosarcoma in vitro model [3, 12, 13, 22]. The mecha-
nism of cytotoxicity in the UMR106 osteosarcoma cells
seems to be related to free radical production as well as to
an increase in apoptosis levels [4, 22, 23]. The purposes of
the present work are to investigate the eVect of three
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768 Cancer Chemother Pharmacol (2008) 61:767–773vanadium complexes: one with glucose (GluVO), other
with trehalose (TreVO) and the last one with aspirin
(VOAspi), on adhesion, migration and colony formation in
the osteosarcoma UMR106 cell line. We have also investi-
gated the role of protein-kinase A (PKA) in the anticarcino-
genic properties of these vanadium compounds.
Materials and methods
Materials
Dulbecco’s modiWed Eagle’s medium (DMEM), trypsin-
EDTA and fetal bovine serum (FBS) were from Gibco
(Life Technology, Buenos Aires, Argentina), and tissue
culture disposable material was from Orange ScientiWc
(Buenos Aires, Argentina). All other chemicals and
reagents were obtained from commercial sources and were
of analytical grade. Vanadyl(IV) complexes were synthe-
sized as previously described and characterized by infrared
spectroscopy as previously reported [3, 12, 14]. The FT-IR
results indicate that the samples of the complexes have
chemical purity. For experiments, fresh solutions of TreVO
and GluVO were made by dissolving the complexes in
water. On the other hand, VOAspi was dissolved in a mix-
ture of ethanol and distilled water (1:1).
Cell culture and incubations with vanadium compounds
UMR106 rat osteosarcoma cells were grown in DMEM
containing 10% FBS, 100 U/ml penicillin and 100 lg/ml
streptomycin at 37°C in 5% CO2 atmosphere [5]. Cells
were seeded on 75 cm2 Xasks and sub-cultured using tryp-
sin-EDTA. For experiments, osteoblast-like cells were
placed on multi-well plates and incubated in 10% FBS
media supplemented with the addition of diVerent doses of
vanadium compounds during the periods of time indicated
in the legends of the Wgures.
Cell adhesion assay
The adhesion assay was performed as it was previously
reported [21]. BrieXy, cells were plated in DMEM-10%
FBS on 24 well plates, at a seeding density of 105 cell/ml,
in the presence of diVerent doses of vanadium compounds.
Cells were allowed to adhere for 1 h at 37°C. Each well was
then washed with phosphate-buVered saline (PBS), Wxed
with methanol for 10 min and stained with Giemsa. The
number of adhered cells was evaluated by microscopy,
counting several representative Welds per well. Cell spread-
ing was assessed by the observation of stained cells that
presented more than one corner, in several representative
microscopic Welds per well.
Localization of actin Wbres by immunoXuorescence 
analysis
Cells were plated in DMEM-10% FBS in the presence or
absence of diVerent vanadium compounds on coverslips,
allowed to attach for 1 h at 37°C. After incubation, cells
were Wxed with 4% p-formaldehyde in PBS for 15 min,
permeabilized with cold methanol for 4 min, and stained
with Xuorescein-labelled palloidin (1:100) for 1 h at room
temperature. Coverslips were mounted in a Vectastain
mounting liquid, and images were recorded and analysed
using a Nikon-5000 Xuorescence microscope and a digital
camera.
Cell migration assay
Cell migration was assessed by an in vitro wound assay [1].
ConXuent monolayers of UMR106 cells were wounded by
scratching lines with a yellow pipette tip. After washing
with culture media, tumoral cells were incubated for 12 h in
DMEM—10% FBS, with or without vanadium complexes.
After this incubation period, the monolayers were Wxed and
stained with Giemsa. The migration distance was evaluated
with a calibrated ocular, assessing the distance between the
borders of the wound.
Clonogenicity assay
UMR106 cells were seeded in DMEM—10% FBS at a den-
sity of 100 cells/well and allowed to adhere for 24 h. Cells
were cultured with diVerent doses of vanadium complexes
during 10 days, replacing the media every day. After this
culture period, the cells were Wxed and stained with
Giemsa. Colony formation units were evaluated counting
the number of colonies/well in a 5£ magniWcation Weld.
Only colonies with more than 10 cells were evaluated [1].
Stability studies
The stability studies were carried out by measuring the UV-
visible spectra of vanadium complexes. BrieXy, 20 mM con-
centration of vanadium complexes were dissolved in water
or in DMEM, and the visible spectra of the solutions were
measured for diVerent periods of time. Complex degradation
was evaluated by measuring the decrease in the intensity of
the characteristic bands of absorbance for each compound as
previously reported [3, 12, 14]. After that, the absorbance of
the solutions was graphicated against the time, and the
resulting linear graphics were analysed to obtain kinetic
parameters (t1/2: lapse of time to cause a diminish of one-half
of concentration; Kd: degradation constant). When no linear
graphics were obtained, the Wrst derivative was plotted and
the kinetic parameters were obtained.123
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Three independent experiments were run for each experi-
mental condition. Results are expressed as the
mean § SEM. Statistical analysis of the data was per-
formed by Student’s t test.
Results
EVect of vanadium complexes on osteosarcoma cell 
adhesion and spreading
The investigation of cell adhesion and spreading are impor-
tant events in cell survival. In particular, in tumoral cells
these processes are the Wrst series of events fundamental for
cancer metastasis. In a Wrst series of experiments we evalu-
ated the action of vanadium(IV) complexes on cell adhe-
sion/spreading in a model of osteosarcoma cells in culture.
Treatment with vanadium(IV) complexes for 1 h, inhibited
both parameters in a dose-dependent manner (Fig. 1).
GluVO and TreVO showed the maximal response at 5 lM.
Both vanadyl complexes diminished cell adhesion nearly
40% (P < 0.001, diVerences vs. basal) (Fig. 1a), while at
this vanadium concentration cell spreading was inhibited
55% of basal (P < 0.001) (Fig. 1b). On the other hand,
VOAspi showed a weaker eVect than GluVO and TreVO
on cell adhesion and spreading, decreasing these parame-
ters by about 25% of the basal at 5 lM (P < 0.001), in this
model of tumoral cells. Concentrations over 5 lM of the
three complexes were also tested. However, these concen-
trations caused deleterious eVects related to cell death that
interfere with the adhesion process. The inhibitory eVect of
the three vanadium compounds on cell adhesion and
spreading was completely reversed by the treatment with
0.5 lM of PKA inhibitor H89 (Table 1).
Studies of cytoskeleton actin by Xuorescence microscopy
To investigate the mechanism of the inhibitory eVect of
vanadium complexes on cell adhesion, we analysed their
action over actin Wbres. Untreated cells (control, Fig. 2a)
showed polymerisation of actin into stress Wbres as well as
cytoplasm extensions indicative of correct adhesion to the
culture plate. Treatment with 5 lM of vanadium complexes
for 1 h (Fig 2b–d) decreased the formation of stress Wbres.
A few number of cells were also found in the dishes, con-
sistent with the results of the adhesion assay (Fig. 1). The
remaining cells showed an altered round and condensed
morphology with no evidence of actin Wbres. It can also be
observed that a tendency of the cells to agglutinate, an
eVect that was more evident after VOAspi treatment
(Fig. 2d). The inhibitory eVect of vanadium compounds on
the formation of stress Wbres was partially prevented by the
co-treatment with the protein-kinase A inhibitor, H89
(Fig. 2e, f). These results suggest that in UMR106 osteosar-
coma cells, vanadium complexes inhibit actin polymerisa-
tion, at least in part, by suppressing the PKA mediated
phosphorylation.
Evaluation of the migration capacity of UMR106 cells
In the invasion process, cell migration to surrounding tis-
sues is a vital important process. The eVect of vana-
dium(IV) complexes on the migration of osteosarcoma
cells was assessed using in vitro wound assay. In the con-
trol untreated-culture, immediately after scratching the
monolayer, the wound borders were well deWned. After
Fig. 1 EVect of vanadium compounds on cell adhesion (a) and spread-
ing (b). UMR106 cells were allowed to adhere for 1 h in the presence
of the doses of vanadium complexes as indicated in the Wgures. Then,
the number of adhering cells (a) and the number of spreading cells (b)
per Weld were evaluated. Results are expressed as % Basal and repre-

















































770 Cancer Chemother Pharmacol (2008) 61:767–77312 h of culture, cells migrated to the centre of the wound to
repair the damage. Figure 3a showed that under basal con-
ditions, UMR106 cells have the capacity to migrate into the
wound, exhibiting cytoplasm protrusions to the edge of
migration. Treatment with 5 lM GluVO signiWcantly sup-
pressed migration, the cells did not show repair capacity,
remaining in the border of the wound (Fig. 3b). The quanti-
Wcation of cell migration (Table 2a) shows that the treat-
ment of UMR106 osteosarcoma cells with GluVO, TreVO
and VOAspi signiWcantly inhibited cell migration in a dose-
dependent fashion. The role of PK-A was investigated
treating the osteoblast-like cells with 0.5 lM of H89, a PKA
inhibitor. As it is shown in Table 2b, the inhibitory eVect of
vanadium compounds on cellular migration was partially or
totally prevented by the addition of H89 for GluVO or the
other two complexes, respectively.
Vanadium compounds inhibited colony formation
Finally we evaluated the ability of GluVO, TreVO and
VOAspi to inhibit UMR106 cell-colony formation. Treat-
ment with vanadyl(IV) complexes for 10 days inhibited the
formation of colonies in a dose-dependent manner
(Table 3). However, the inhibition caused by GluVO and
Table 1 PKA inhibitor H89 reverses the inhibitory action of vanadium compounds on cell adhesion and spreading 
UMR106 cells were allowed to adhere for 1 h in the presence of 0.5 lM H89 alone or/and plus 5 lM vanadium complexes. Then, the number of
adhering cells and the number of spreading cells per Weld were evaluated. Results are expressed as % Basal and represent the Media § SEM of
three independent experiments
* P < 0.001, ** P < 0.01
Basal GluVO TreVO VOAspi
+0.5 lM H89 5 lM +0.5 lM H89 5 lM +0.5 lM H89 5 lM +0.5 lM H89
Adhesion 100 § 8 105 § 7 71 § 5** 99 § 7 78 § 7** 91 § 6 60 § 5* 88 § 6
Spreading 100 § 8 105 § 8 52 § 6** 81 § 8 71 § 7** 84 § 7 42 § 5* 81 § 6
Fig. 2 Localization by 
ImmunoXourescence of actin 
Wbres. UMR106 monolayers 
were treated for 1 h with 5 lM 
vanadium compounds (b–d), a 
basal condition was also includ-
ed (a) for comparative reasons. 
The action of vanadium com-
plexes was partially reversed by 
the treatment with 0.5 lM H89 
(e, f). ImmunoXuorescence as-
say was performed as described 
in Materials and methods 
(MagniWcation 100£)123
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TreVO.
Stability studies
The stability studies show that vanadium complexes were
much more stable in culture media than in water (Table 4).
We found that in DMEM all the three compounds presented
an exponential decay in the concentration as measured by
the spectra of the fresh solutions. We can make a ranking of
stabilities for the three compounds both in water and in
DMEM. In water the relative stabilities were:
GluVO>TreVO>VOAspi, whereas in DMEM it was:
TreVO>GluVO>VOAspi.
Discussion
Over the past two decades, it has been reported that vana-
dium derivatives exhibiting antitumoral properties become
an interesting group of non-platinum antineoplastic drugs
[10, 15]. In particular, because vanadium is mainly accu-
mulated in bone, it seems reasonable to think that its deriv-
atives could be useful in the treatment of bone-tumour
metastasis. On the other hand, recent studies demonstrate
that vanadium behaves as an osteogenic agent, promoting
the mineralization process in bone [16]. Our group has
demonstrated that high concentrations of vanadium com-
pounds exert deleterious eVects on osteoblast-like cells in
Fig. 3 Vanadium complexes 
inhibit monolayer wound heal-
ing in UMR106 cells. In basal 
conditions (a) UMR106 cells are 
able to heal the wound, while the 
treatment with GluVO for 12 h 
inhibits the repair process by 
inhibiting cell migration. Cell 
monolayers were Wxed and 
stained with Giemsa, and cell 
migration was evaluated by light 
microscopy (MagniWcation 
10£)
Table 2 The PKA inhibitor H89 reverses inhibition of cell migration
by vanadium complexes 
UMR106 cells were scratched with a yellow tip and allowed to heal the
wound for 12 h in the absence or presence of diVerent doses of vana-
dium complexes (A). To investigate the role of PKA in the inhibition
of cell migration, the assay was carried out in the presence of 5 lM
vanadium derivatives plus 0.5 lM H89 (B). Results are expressed as %
Basal and represent the Media § SEM of three independent experi-
ments
(A) DiVerences versus basal (0 lM Vanadium complexes):
*P < 0.001, **P < 0.02, ***P < 0.01 
(B) DiVerences versus treated cells: *P < 0.001, **P < 0.05 
Cell migration (A)
(lM) GluVO TreVO VOAspi
0 100 § 0 100 § 1 100 § 6
2.5 62 § 11*** 71 § 5** 65 § 9 
5 57 § 12*** 44 § 5* 36 § 13**
Cell migration (B)
+0.5 lM H89
Basal 100 § 2 96 § 0
5 lM GluVO 53 § 6 73 § 6**
5 lM TreVO 74 § 4 89 § 10
5 lM VOAspi 48 § 4 85 § 4*
Table 3 Inhibition of colony formation by vanadium complexes 
After 10 days of culture, vanadium compounds inhibited UMR106
cell-colony formation, in a dose–response fashion. Results are ex-
pressed as % Basal and represent the Media § SEM of three indepen-
dent experiments
*P < 0.001, **P < 0.002. DiVerences are versus basal condition (0 lM
Vanadium complexes)
Colony formation
(lM) GluVO TreVO VOAspi
0 12 § 1 13 § 1 12 § 1
2.5 5 § 0* 11 § 0.4 4 § 1*
5 1 § 0* 9 § 0.3** 1 § 0*123
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oxygen species production [4, 6, 22]. In the present work
we studied the antineoplastic properties of three vana-
dium(IV) complexes with biologically relevant ligands. We
found that vanadium derivatives inhibited both cell adhe-
sion and spreading (Fig. 1). Cell adhesion to the extracellu-
lar matrix (ECM) is a complex event that depends on
multiple factors such as the correct cytoskeleton organiza-
tion as well as the interaction of the actin Wbres with adhe-
sion molecules (i.e. integrins) [7, 17, 19]. This interaction
eventually triggers an intracellular signalling pathway that
controls cell shape and motility as well as cell proliferation
[17]. Multiple tyrosine kinases and phosphotyrosine pro-
teins have been identiWed to be involved in these processes.
Besides, protein tyrosine phosphatases (PTPases) have
been related to cell adhesion [30].
The inhibitory eVect on cell adhesion caused by vana-
dium(IV) compounds could be partially explained by two
phenomena. First, vanadium is a well-known enhancer of
phosphoprotein levels, especially for those proteins that are
phosphorylated on tyrosine residues by inhibiting PTPases
and/or activating tyrosine kinases [26, 28]. It has been dem-
onstrated that with a high level of tyrosine phosphorylation
there is a rapid reorganization of the actin cytoskeleton
[25]. Second, it has been demonstrated that agonists of
cAMP/PKA signalling cascade may cause signiWcant
changes in the cytoskeleton architecture such as dissolution
of stress Wbres and induction of morphological changes in
diVerent cell types [17, 18]. Moreover, cAMP/PKA regu-
lates the disassembly of focal adhesion and also causes the
dissolution of actin Wlaments as well as a decrease in the
phosphotyrosine content of paxillin, aVecting in last
instance cell adhesion as well as motility [17]. There are
results indicating that vanadium can enhance PKA activity
both in vivo and in vitro [18, 26].
Moreover, our results show that the PKA pathway could
mediate the vanadium-induced inhibition of stress Wbres-for-
mation, because the treatment of the osteosarcoma cells with
the PKA-inhibitor H89, partially reversed the observed
eVect (Table 1). In consequence, both, cell migration and
clonogenicity, are diminished (Fig. 3; Tables 2a, b, 3).
In conclusion our study demonstrates that the three vana-
dium(IV) derivatives markedly inhibit the key events of
tumour cell dissemination: cell adhesion, migration and
clonogenicity. We have also demonstrated that there is a
PKA-dependent mechanism involved in the antitumoral
action of GluVO, TreVO and VOAspi.
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